NDAINJECTIONINJECTABLE
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of…
Clinical Trials (5)
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
Started Jan 2010
68 enrolled
Lung Transplantation
An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients
Started Dec 2009
414 enrolled
Kidney Transplantation
A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients
Started Nov 2009
23 enrolled
Kidney Transplantation
Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Started Aug 2009
43 enrolled
Stable Renal Transplant Recipients
Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Started Apr 2009
23 enrolled
Gastrointestinal LesionsSigns and Symptoms, Digestive